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Identity 
Alias: Signet ring carcinoma or isolated cell type 
carcinoma. 
Inheritance: Autosomal dominant with high 
penetrance (about 80%), average age of onset is in the 
4th decade of life but it could be as early as the teens to 
the seventies. Germline mutations in CDH1 gene have 
been associated with this condition (Gayther et al., 
1998; Guilford et al., 1998). 
Clinics 
Note 
Criteria for diagnosis (Brooks-Wilson et al., 2004):  
- Two or more cases of gastric cancer in a family, with 
at least one diffuse gastric cancer diagnosed before age 
50 years. 
- Three or more cases of gastric cancer in a family, 
diagnosed at any age, with at least one documented 
case of diffuse gastric cancer. 
- An individual diagnosed with diffuse gastric cancer 
before 45 years of age. 
- An individual diagnosed with both diffuse gastric 
cancer and lobular breast cancer (no other criteria met). 
- One family member diagnosed with diffuse gastric 
cancer and another with lobular breast cancer (no other 
criteria met). 
- One family member diagnosed with diffuse gastric 
cancer and another with signet ring colon cancer (no 
other criteria met). 
Phenotype and clinics 
HDGC forms less than 3% of all gastric cancers (Stone 
et al., 1999). It often affects younger people  
in contrast to the other types of gastric cancer. It 
consists of scattered clusters of poorly differentiated 
cells involving a large area of the stomach without a 
macroscopically recognisable margin or formation of a 
mass or ulcer (linitis plastica).  
There is no known association between genotypic and 
phenotypic character of the disease (Kaurah and 
Huntsman, 2006).  
Malignant risk: Four fifths of female carriers with 
CDH1 gene mutations are estimated to develop HDGC 
by age of 80 years with an additional 40% risk for 
lobular breast cancer, adding up to 90% for both 
cancers, while two thirds of males are expected to 
develop gastric cancer by the same age (Paul et al., 
2001). 
Treatment 
Aim of the management is: (1) Curative treatment 
through early detection and resection of the tumour 
completely, but unfortunately gastric cancer especially 
HDGC are usually incurable at presentation. (2) 
Identifying Germline mutation in CDH1 can provide 
help and support for family members who are 
unaffected but carrier of the genetic mutations by 
developing a plan to reduce the risk of cancer (Brooks-
Wilson et al., 2004), through either (a) prophylactic 
gastrectomy which may be life saving as cancer cells 
have been detected in all resected stomach specimens 
in asymptomatic carriers (Huntsman et al., 2001), but 
with high morbidity and mortality (22-30% and 4-5% 
respectively (Kelsen et al., 2008)), or through (b) 
extensive biannual chromo endoscopic surveillance 
which has its limitation in detecting submucosal lesions 
in a normal looking mucosa, therefore the best 
preventive approach is yet to be established (Cisco et 
al., 2008). 
In view of increase risk of colorectal cancer by 2-3 
times and lobular breast cancer in females, surveillance 
colonoscopy every 3-5 years and regular MRI check of 
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the breast may be required (Cisco et al., 2008; Porter et 
al., 2002). 
Prognosis 
Overall survival in gastric cancer is poor with 28% at 5 
years and 20% at 10 years. However if the cancer is 
detected at early stages (i.e. confined to mucosa and 
submucosa), >90% will be alive at 5 years compare to 
10-20% in advanced gastric cancer even when 
potentially curative surgery has been carried out 
(Kelsen et al., 2008; Leung et al., 2009). 





Description: The gene consists of 16 exons and a 65-
kb-long intron 2 that span around 100 kb (Berx et al., 
1995). 
Protein 
Description: E cadherin is a transmembrane calcium 
dependant glycoprotein (728 AA) with cytoplasmic 
domain which binds to actin cytoskeleton via catenins 
(catenin alpha, catenin beta and catenin gamma), single 
transmembrane domain, and extracellular domains 
which adhere to neighbouring cells and form a tight 
homophilic bond which is an important part in cell-cell 
adhesions, tissue architecture, cell differentiations and 
proliferations (Conacci-Sorrell et al., 2002; Roy and 
Berx, 2008). 
Function: CDH1 gene encodes for Cadherin protein 
which plays an important role in maintaining normal 
cell physiology like differentiation, growth, motili y 
and tissue architecture through tight cell-cell adhesions 
(Conacci-Sorrell et al., 2002; Robertson and 
Jankowski, 2008). 
Loss of cell adhesions have been noted in cancers for a 
long time. CDH1 suppression has been associated with 
poorly differentiated, aggressive, metastatic cancers. 
Mutation in E-cadherin is also associated with breast, 
colorectal cancers, thyroid, endometrial, ovarian, head 
and neck, skin, prostate, bladder cancer and other 
tumours (Birchmeier, 1995). 
Mutations 
Germinal: Germline mutations in CDH1 have been 
associated with HDGC. First mutations were described 
by Guilford et al. in three Maori families in New 
Zealand in 1998 (Guilford et al., 1998). Nowadays 
more than 50 different types of mutations have been 
described and new ones are emerging (Robertson and 
Jankowski, 2008). Types of mutations described are 
mainly truncating and missense mutations. 
Up to 50% of families meeting the criteria above, 
which was set by the International Gastric cancer 
Linkage Consortium (IGCLC) in 2004, will have 
mutations in CDH1 (Brooks-Wilson et al., 2004).  
Promoter methylation of the wild type allele in the 
mutated CDH1 is associated with loss of gene 
expression and might work as a "second genetic hit" 
predisposing to cancer and explain the absence of loss 
of heterozygosity in this condition (Grady et al., 2000). 
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